| pubmed-article:11063825 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11063825 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:11063825 | lifeskim:mentions | umls-concept:C0026769 | lld:lifeskim |
| pubmed-article:11063825 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11063825 | lifeskim:mentions | umls-concept:C0021758 | lld:lifeskim |
| pubmed-article:11063825 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:11063825 | lifeskim:mentions | umls-concept:C0015980 | lld:lifeskim |
| pubmed-article:11063825 | lifeskim:mentions | umls-concept:C0021745 | lld:lifeskim |
| pubmed-article:11063825 | lifeskim:mentions | umls-concept:C0237753 | lld:lifeskim |
| pubmed-article:11063825 | lifeskim:mentions | umls-concept:C0175630 | lld:lifeskim |
| pubmed-article:11063825 | lifeskim:mentions | umls-concept:C0547047 | lld:lifeskim |
| pubmed-article:11063825 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:11063825 | pubmed:dateCreated | 2000-12-1 | lld:pubmed |
| pubmed-article:11063825 | pubmed:abstractText | Systemic administration of interferon (IFN)-beta has been recently approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). The immunological mechanism by which IFN-beta ameliorates MS is still partially unknown. We measured the number of blood circulating CD4(+), CD4(-), CD8(+), and CD8(-) T cells secreting IFN-gamma and IL-4 in 26 RRMS patients followed for up to 9 months of an alternate day s.c. treatment with 8x16 IU of IFN-beta1b. Compared to pre-treatment values, a significant (P<0.05) reduction of CD4(+), CD4(-), CD8(+) and CD8(-) cells producing IFN-gamma and of CD4(+) and CD4(-) cells producing IL-4 was observed in MS patients. The IFN-beta-associated effect was evident soon after the beginning of the treatment and persisted for the entire follow-up period. We did not observe any effect of IFN-beta treatment on the percentage of IL-4-producing CD8(+) and CD8(-) cells nor in that of natural killer (NK) cells producing IFN-gamma. Our results show that IFN-beta treatment in MS patients induces a profound and persistent down-regulation of the number of circulating T cells secreting IFN-gamma and IL-4 thus suggesting a broader rather than a specific immunomodulatory effect of IFN-beta in MS. | lld:pubmed |
| pubmed-article:11063825 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11063825 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063825 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11063825 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063825 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063825 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063825 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063825 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11063825 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11063825 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:11063825 | pubmed:issn | 0165-5728 | lld:pubmed |
| pubmed-article:11063825 | pubmed:author | pubmed-author:LangRR | lld:pubmed |
| pubmed-article:11063825 | pubmed:author | pubmed-author:MartinoGG | lld:pubmed |
| pubmed-article:11063825 | pubmed:author | pubmed-author:BrambillaEE | lld:pubmed |
| pubmed-article:11063825 | pubmed:author | pubmed-author:ComiGG | lld:pubmed |
| pubmed-article:11063825 | pubmed:author | pubmed-author:MartinelliVV | lld:pubmed |
| pubmed-article:11063825 | pubmed:author | pubmed-author:FranciottaDD | lld:pubmed |
| pubmed-article:11063825 | pubmed:author | pubmed-author:FurlanRR | lld:pubmed |
| pubmed-article:11063825 | pubmed:author | pubmed-author:PaninaPP | lld:pubmed |
| pubmed-article:11063825 | pubmed:author | pubmed-author:BergamiAA | lld:pubmed |
| pubmed-article:11063825 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11063825 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:11063825 | pubmed:volume | 111 | lld:pubmed |
| pubmed-article:11063825 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11063825 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11063825 | pubmed:pagination | 86-92 | lld:pubmed |
| pubmed-article:11063825 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:11063825 | pubmed:meshHeading | pubmed-meshheading:11063825... | lld:pubmed |
| pubmed-article:11063825 | pubmed:meshHeading | pubmed-meshheading:11063825... | lld:pubmed |
| pubmed-article:11063825 | pubmed:meshHeading | pubmed-meshheading:11063825... | lld:pubmed |
| pubmed-article:11063825 | pubmed:meshHeading | pubmed-meshheading:11063825... | lld:pubmed |
| pubmed-article:11063825 | pubmed:meshHeading | pubmed-meshheading:11063825... | lld:pubmed |
| pubmed-article:11063825 | pubmed:meshHeading | pubmed-meshheading:11063825... | lld:pubmed |
| pubmed-article:11063825 | pubmed:meshHeading | pubmed-meshheading:11063825... | lld:pubmed |
| pubmed-article:11063825 | pubmed:meshHeading | pubmed-meshheading:11063825... | lld:pubmed |
| pubmed-article:11063825 | pubmed:meshHeading | pubmed-meshheading:11063825... | lld:pubmed |
| pubmed-article:11063825 | pubmed:meshHeading | pubmed-meshheading:11063825... | lld:pubmed |
| pubmed-article:11063825 | pubmed:meshHeading | pubmed-meshheading:11063825... | lld:pubmed |
| pubmed-article:11063825 | pubmed:meshHeading | pubmed-meshheading:11063825... | lld:pubmed |
| pubmed-article:11063825 | pubmed:meshHeading | pubmed-meshheading:11063825... | lld:pubmed |
| pubmed-article:11063825 | pubmed:meshHeading | pubmed-meshheading:11063825... | lld:pubmed |
| pubmed-article:11063825 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11063825 | pubmed:articleTitle | Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4. | lld:pubmed |
| pubmed-article:11063825 | pubmed:affiliation | Neuroimmunology Unit-DIBIT, Dept. of Neuroscience, San Raffaele Scientific Institute, Via Olgettina 58, 20132, Milan, Italy. | lld:pubmed |
| pubmed-article:11063825 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11063825 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11063825 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11063825 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11063825 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11063825 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11063825 | lld:pubmed |
